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INTRODUCTION
By remodeling the actin cytoskeleton, Rho GTPases regulate various cellular processes, such as proliferation, migration, cell adhesion and cell shape (Etienne-Manneville and Hall, 2002) .
They are activated by the Dbl family of Rho Guanine Nucleotide Exchange Factors (RhoGEFs), which accelerates their GDP/GTP exchange rate (Rossman et al., 2005) .
RhoGEFs represent a large family (over seventy members in mammals) of complex proteins with numerous signaling domains, but they almost invariably contain a functional tandem, including a Dbl Homology (DH) domain responsible for guanine nucleotide exchange, followed by a Pleckstrin Homology (PH) domain, which targets the GEF to the plasma membrane and/or regulates nucleotide exchange (Chhatriwala et al., 2007; Lutz et al., 2007; Rojas et al., 2007; Rossman et al., 2003; Rossman et al., 2005) . Deregulation of Rho GTPase function has been associated with various human disorders, including mostly cancer and metastasis, but also cardiovascular and hepatic disease, bacterial and viral pathogenesis, and developmental disorders, including neurodegenerative diseases (Sahai and Marshall, 2002; Toksoz and Merdek, 2002) . Consistently, many Dbl family RhoGEFs have been isolated based on their oncogenic potency, which often results from a truncation of the protein, leading to uncontrolled GEF activity and subsequent aberrant Rho GTPase activation (Eva and Aaronson, 1985; Katzav et al., 1989; Miki et al., 1993; Whitehead et al., 1995; Whitehead et al., 1996) . Rho GTPases and their GEFs therefore represent challenging targets for inhibition, not only to understand their function but also in pathology, and strategies to inhibit their function are actively being sought (Bos et al., 2007) . The main issue when trying to inhibit RhoGEFs is to achieve a high degree of specificity within such a complex and large family of related proteins, and to target protein-protein interactions which are not yet well characterized. To date only few strategies have been devised successfully, allowing the discovery of chemical
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and peptidic RhoGEF inhibitors, that block the activation of Rho GTPases by their cognate GEFs (Blangy et al., 2006; Gao et al., 2004; Schmidt et al., 2002) . We described previously peptide aptamer screening as such a strategy, which enabled us to discover the first RhoGEF inhibitor . Peptide aptamers are short peptides constrained by a bacterial Thioredoxin (TrxA) scaffold, which bind to their protein targets with high affinity (Baines and Colas, 2006; Hoppe-Seyler et al., 2004) . This technology has been applied initially to the discovery of inhibitors against various intracellular targets, involved mainly in cell-cycle control or cell survival (Butz et al., 2000; Colas et al., 1996; Crnkovic-Mertens et al., 2003; Fabbrizio et al., 1999; Martel et al., 2006; Nouvion et al., 2007) . Peptide aptamers present interesting advantages over other classes of inhibitory molecules, mainly because of their simple design and their high degree of binding specificity, which enables them to discriminate between closely related proteins within a functional family. But most remarkably, these highly combinatorial proteins are screened and designed to function inside living cells and allow the study of protein function within complex regulatory networks (Bickle et al., 2006) .
The RhoGEF inhibitor we have isolated using this aptamer screening strategy, called TRIP (Trio Inhibitory Peptide ), targets specifically the DH2-PH2 tandem of the RhoGEF Trio and inhibits its activation of RhoA both in vitro and in intact cells, reverting the neurite retraction phenotype induced by Trio DH2-PH2 in PC12 cells . Most interestingly, although TRIP was initially selected with the TrxA scaffold, it remained equally active as a linear peptide .
The recently identified oncogenic RhoGEF Tgat is an interesting novel candidate target for such peptidic inhibitors. Indeed, Tgat has been identified from Adult T-Cell Leukemia (ATL) patient cells as a gene with oncogenic potency and originates from an alternate splicing of the trio gene (hence the name Tgat, for Trio-related transforming Gene in ATL Tumor cells) (Yoshizuka et al., 2004) . Tgat retains only the RhoA-specific DH2 domain of Trio and, hal-00392842, version 1 -9 Jun 2009 instead of the associated PH2 domain, carries a unique C-terminal sequence of 15 amino acids. It induces cell transformation and tumor formation in nude mice (Yoshizuka et al., 2004) and has been proposed to enhance tumor invasion by stimulating Matrix MetalloProteinases (MMPs) via the RECK protein and by activating the transcription factor NF-B, which plays a crucial role in tumorigenesis, including ATL .
In this context, designing peptide inhibitors against the RhoGEF Tgat is very challenging, not only from a pathological point of view, but also from a conceptual perspective, addressing the important issue of specificity when targeting proteins which, like RhoGEFs, belong to families with high homologies.
In this study we devised an optimization screen based on the TRIP peptide, which allowed us to identify a novel peptide that is active as a Tgat inhibitor, targeting its GEF activity in vitro in a highly specific manner. Moreover, it strongly reduces its oncogenic properties in vivo, most remarkably by decreasing foci formation and tumor development in nude mice.
Our peptide optimization strategy identifies the first inhibitor of the Tgat oncogene, and demonstrates that aptamers can be used to interfere with RhoGEF functions in vivo with exquisite specificity. hal-00392842, version 1 -9 Jun 2009
RESULTS

The GEF activity of the DH domain is required for Tgat-induced transformation.
In order to design inhibitors that would target Tgat oncogenic activity, we first established whether the GEF activity of Tgat is involved in transformation. To do so, we designed a Tgat mutant, called Tgat L190E , which harbors a point mutation in its DH domain, the equivalent mutation in Trio DH2-PH2 being known to abolish its exchange activity on RhoA ( Figure   1A ) (Bellanger et al., 2003) . We established NIH3T3 cell lines stably expressing similar levels of GFP or GFP-tagged Tgat or Tgat L190E ( Figure 1B , lower panel), and analyzed the ability of these constructs to activate RhoA and to induce transformation. We measured RhoA 
Strategy to identify a Tgat inhibitor.
Since the GEF activity of Tgat is necessary for transformation, molecules that block this biochemical activity could also inhibit its transforming potential. We previously identified a peptide aptamer, TRIP , which targets the RhoA-specific DH2-PH2 tandem of Trio Figure 2A ). However, none of the mutants exhibited stronger inhibition towards Trio DH2-PH2 and were not further investigated on Tgat.
We next reasoned that peptides that would bind stronger to the GEF domain may also be better at inhibiting its activity. We thus generated a library of peptide aptamers derived from TRIP by random mutagenesis, which we screened for GEF binding in a yeast two-hybrid assay. We chose a system in which the threshold of interaction detection can be modulated by the concentration of the 3-aminotriazole (3-AT) drug (Sardet et al., 1995) . Since Tgat is toxic in yeast, we used Trio DH2-PH2 to screen this TRIP-like peptide library. Thirty-five independent clones bound to Trio DH2-PH2 at concentrations of 3-AT at which no interaction with TRIP was detected anymore (80-120mM). These clones were then produced as GSTfusions and analyzed for their inhibition of Trio DH2-PH2, using the [ 3 H]-GDP dissociation assay. As shown in Figure 2B , 10 of them were stronger inhibitors than TRIP . Analysis of their sequence revealed that they contained one to four mutations per peptide, and that, consistently, most of them resided within the two regions identified as crucial for the inhibitory properties of TRIP ( Figure 2B , shaded residues).
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We then analyzed the inhibitory activity towards Tgat of TRIP E32G and TRIP
T16M/L17S
, the two TRIP-like peptides that displayed the highest inhibition on Trio DH2-PH2 ( Figure 2B ). Both peptides inhibited Tgat GEF activity in a dose-dependent manner in a kinetics fluorescence assay, while GST alone (not shown) or GST-TRIP , at the same concentrations, had no effect ( Figure 2C ). Accordingly, the apparent inhibition constant (Ki app ) of TRIP towards Tgat was 89 ± 33 M, and decreased to 7.4 ± 5 M for TRIP E32G and 5.1 ± 4 M for TRIP T16M/L17S
( Figure 2D ). These data show that TRIP E32G and TRIP T16M/L17S are both about 15 times more efficient than TRIP at inhibiting the exchange activity of Tgat.
Interestingly, the optimized peptides were equally efficient on Tgat and on Trio DH2, as
shown by their similar Ki app values ( Figure 2C and 2D). This suggests that the unique Cterminal extension of Tgat is not involved in the inhibitory mechanism of the optimized peptides, and is consistent with the fact that this sequence does not interfere with the GEF activity in vitro (data not shown).
Inhibition by TRIP peptides is specific for Tgat.
We then analyzed the specificity of the optimized TRIP peptides, by testing their inhibitory properties on other related RhoGEFs. We had shown previously that TRIP is not active on the RhoA-specific GEFs p115RhoGEF, Lbc, p63RhoGEF, nor on Dbl and unpublished results). Similarly, when tested in mant-GTP fluorescence kinetics at a concentration at which Tgat is fully inhibited, TRIP E32G and TRIP T16M/L17S had no effect on the exchange activities of these closely related RhoGEF/Rho-GTPase tandems, p115RhoGEF/RhoA, Lbc/RhoA, Dbl/RhoA, and even the very closely Trio-related p63RhoGEF/RhoA (70% identity within the DH-PH module), or Trio DH1-PH1/RhoG (40% identity with Tgat) (Figure 3 ). Taken together, these data show that the optimized TRIP peptides are highly specific for Tgat and Trio DH2.
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TRIP E32G inhibits the transforming activity of Tgat in vivo.
We next analyzed whether our TRIP-like peptides inhibited Tgat-mediated RhoA activation in intact cells. For that purpose, NIH3T3 cells stably expressing Tgat were transfected with the GFP-tagged TRIP-like peptides or GFP alone, and RhoA activation levels were assessed by the GST-RBD pull-down assay ( Figure 4 ). Although TRIP E32G and TRIP T16M/L17S inhibited the in vitro GEF activity of Tgat to a similar extent, TRIP E32G was more efficient than TRIP T16M/L17S at inhibiting Tgat-mediated activation of RhoA in cells ( Figure 4A -B). These data show that, in addition to its effect on in vitro guanine nucleotide exchange, TRIP
E32G
inhibits Tgat GEF activity also in intact cells.
In order to verify the exquisite specificity of our peptide towards Tgat/DH2 in vivo, we analyzed by GST-RBD pull-down assay whether TRIP E32G could inhibit oncogenic Dblmediated RhoA activation in intact cells. Figure 4C shows that, in contrast to its effect on Tgat activity, TRIP E32G was not able to inhibit RhoA activation by Dbl, confirming the in vitro specificity of TRIP E32G towards Tgat.
We then investigated whether TRIP E32G was able to inhibit Tgat-induced transformation. To do so, we stably expressed GST or GST-TRIP E32G in Tgat-expressing NIH3T3 cells and characterized their transforming potential. After 3 weeks of culture, the foci present in Tgatexpressing cells were severely reduced when co-expressing TRIP E32G ( Figure 5A -B). This reduction is not due to a non-specific effect of TRIP E32G on cell proliferation or apoptosis (data not shown). These data show therefore that targeting Tgat GEF activity with TRIP E32G is sufficient to impair Tgat transforming activity. with Tgat, only seven mice had tumors and we observed a delay of about three weeks in the formation of tumors ( Figure 5C ). In addition, even though tumor formation was not abolished, the weight of the tumors was significantly reduced when TRIP E32G was expressed ( Figure   5D ). Altogether, these data show that expression of TRIP E32G strongly reduces Tgat transformation activity in cells and affects tumor formation in nude mice, most likely by inhibiting Tgat-mediated GTP loading of RhoA.
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DISCUSSION
Peptide aptamers as new inhibitors of RhoGEFs.
Because of their deregulation in many human disorders including cancer, Rho GTPases and their activating GEFs represent challenging targets for inhibition. In humans there are only 20
Rho GTPases but more than 70 RhoGEFs, and it appears that signaling specificity is mostly determined by the GEFs, which activate the GTPases at defined timing and location. RhoGEF inhibitors therefore represent an emerging field of investigation.
Here we developed a peptide aptamer screening strategy to inhibit the RhoGEF Tgat, a potential target in the ATL disease. Since Tgat is an isoform of the RhoGEF Trio, which includes the RhoA-specific DH2 domain plus a unique C-terminal sequence, we based our screen on our previously identified Trio inhibitor TRIP , the first peptidic RhoGEF inhibitor described, which targets the DH2-PH2 domain of Trio . Intriguingly, despite the fact that Tgat harbors the Trio DH2 domain, our original TRIP inhibitor was rather ineffective at inhibiting Tgat. This suggests that the PH2 domain of Trio is involved in the mechanism of action of TRIP , and that its replacement by the C-terminal extension decreases TRIP 's ability to inhibit the GEF activity of Tgat.
We show here that GEF inhibitors selected with the peptide aptamer screening approach are readily amenable to structure-activity relationship analysis and optimization. Of the 28 residues located in the active core of TRIP , alanine scanning mapped 9 residues in two regions (residues 9-20 and 28-33) that were critical for the catalytic activity, while 6 had a moderate effect and the others had no effect. We also show that peptide aptamer optimization can be achieved by random mutagenesis combined with a selection screen based on interaction strength. At least one third of the isolated clones yielded stronger inhibition, thus validating the rationale of the screen. The two selected peptides, TRIP E32G and TRIP
T16M/L17S
, were 15-fold more efficient than TRIP and inhibited Tgat GEF activity at concentrations hal-00392842, version 1 -9 Jun 2009 lying in the low micromolar range. Interestingly, mutations found in these clones also fell within the two important regions identified by the Ala-scan. Furthermore, this approach allowed us to turn TRIP into a Tgat inhibitor, which could be achieved with as few as one mutation, E32G. It remains to be determined whether these different amino acids are important for binding to the GEF and/or for inhibition of the exchange reaction.
It should be emphasized that our screening and optimization method is effective, irrespective of the inhibitory mechanism, which is of big advantage for the discovery of inhibitors of protein-protein interactions. The way the original screen was performed, i.e. two-hybrid screening with the GEF as bait in the absence of GTPase, strongly suggests that the target of the peptides is the GEF itself, rather than the GTPase. This is reinforced by the fact that the peptides do not inhibit spontaneous GDP release from RhoA using [ 3 H]-GDP-loaded RhoA (data not shown), and by our specificity data in vitro and in intact cells, which show that other GEF activities towards RhoA are not inhibited (Figure 3 and 4) . At this stage we cannot, however, distinguish between competitive and allosteric inhibition, or even a less likely uncompetitive mechanism.
Remarkably, the characterization of our optimized TRIP peptides clearly shows that gain of efficiency is not associated with loss of specificity. Indeed, none of the RhoA-activating GEFs we tested, in particular the very closely related p63RhoGEF, were affected by either TRIP . In addition, the TRIP peptides did not affect the activity of GEFs with different specificity such as the RhoG/Rac1-specific TrioDH1-PH1.
Peptide aptamers are functional in vivo
Our screening method demonstrates that TRIP E32G is not only effective and specific at inhibiting Tgat GEF activity in vitro, but that it also blocks Tgat-induced cell transformation and tumor formation in vivo. This is the first example of a peptidic RhoGEF inhibitor that is 
Peptide aptamers versus other GEF inhibitor screening strategies.
Besides our peptide aptamer screening approach, other strategies have recently been devised to discover chemical inhibitors of Rho GTPase/GEF tandems, and also other classes of small G proteins, such as the Arf family and their activating GEFs (Blangy et al., 2006; Desire et al., 2005; Gao et al., 2004; Mayer et al., 2001; Shutes et al., 2007; Viaud et al., 2007) .
Computer-assisted virtual screening, for example, identified the NSC23766 compound, based on structure-function information of the Rac1/Tiam1 complex. This powerful molecule inhibits specifically Rac1-induced events in vitro and in vivo, however the targeted associated RhoGEFs include at least Tiam1 and Trio DH1-PH1 (Gao et al., 2004) . In silico screening also yielded the LM11 compound, which inhibits specifically the ARNO/Arf1 interface in vitro and is active in cells (Viaud et al., 2007) . Given their membrane permeability, both NSC23766 and LM11 have the advantage of being easily applied in vivo.
The Yeast Exchange Assay is another screening method that allowed the identification of the TrioDH1-PH1 specific NPPD compound and its analogues (Blangy et al., 2006) . Like peptide
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aptamer screening, this strategy has the advantage over virtual screening of identifying inhibitors directly in cells, and without any bias as to the targeted interaction site.
Finally, in vitro RNA-aptamer screening selected the RNA aptamer M69 as an inhibitor of the Cytohesin/Arf1 tandem (Mayer et al., 2001) . Like peptide-aptamers, these RNA aptamers are highly combinatorial and easily screened, but their application as potential drugs remains limited, due to difficult in vivo delivery. To circumvent this problem, RNA-aptamerdisplacement represents an elegant method, in which a small-molecule library is screened for compounds that displace the RNA-aptamer from its target and reproduce its inhibitory activity (Hafner et al., 2006) .
Our study shows that peptide aptamer screening represents a valid strategy for inhibitor identification that can be applied to a variety of different proteins, because of the in vivo screening method and the highly combinatorial libraries available, yielding strong affinity inhibitors. This is illustrated here by the identification of a highly specific peptidic RhoGEF inhibitor targeting the Tgat oncogene in vitro and in vivo.
When trying to inhibit signaling pathways controlled by small G proteins and their activating GEFs, the challenge is that these are not mere enzymes with a well-defined active site that can be blocked. Rather, protein-protein interactions have to be targeted and the lack of reactive pockets to which inhibitors could bind is a challenging issue. This might in part explain why, although oncogenic Ras has been discovered more than 20 years ago, no inhibitor with clinical validation has been identified. Therefore, research has focused on trying to inhibit the guanine nucleotide exchange factors instead, and recent studies report the successful identification of such inhibitors.
The power of the strategy we used here to identify the TRIP peptides relies on the screening of a highly combinatorial aptamer library, generating immense possibilities of random peptides. This variety makes peptide aptamers very suitable molecules to inhibit complex protein-protein interactions such as the tandem RhoGEF/GTPase, and to discriminate between closely related proteins. One major advantage of this kind of approach is that the screening is cell-based, which gives a direct readout for toxicity and is more stringent. Moreover, peptide aptamers do not mimic cellular targets, which could have non-desired effects in cells. In addition, to circumvent the problem of in vivo delivery when using peptide aptamers, aptamer-displacement screens can be performed, in order to convert an aptamer into a small compound inhibitor (Baines and Colas, 2006) . The advantage is that the corresponding compound targets the same site and shares the same properties as the already characterized peptide.
In conclusion, peptide aptamers represent a promising alternative for the discovery of leads for new therapeutic drugs. protein was eluted with a linear gradient of 2-0 M NaCl in 50 mM Tris pH 7.5. The purified proteins were concentrated on a Vivaspin concentrator (Vivascience AG Inc.) at 18 mg/mL.
Other proteins. Recombinant GST-Trio DH2-PH2, GST-Trio DH1-PH1, GST-Dbl (DH-PH domain), GST-Lbc (DH-PH), GST-p63RhoGEF (DH domain) and GST-RhoG were purified as described previously Souchet et al., 2002) . Expression and purification of GST-p115RhoGEF using the baculo virus system will be described elsewhere.
GST-Peptides. GST-TRIP peptides were purified as described , except that the cell lysate was centrifuged as above, before loading on a GSTrap Fast Flow column (GE Healthcare Inc.) equilibrated with lysis buffer. Peptides were eluted with reduced glutathione (10 mM) in Tris 50 mM pH 7.5 and concentrated on Vivaspin concentrator at about 5-10 mg/mL. 
Optimization of TRIP -
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Nucleotide exchange kinetics assay -Specific exchange rates of Tgat were measured with a fluorescence-based kinetics assay, using a 6His-RhoA construct (gift of Dr Derewenda, Charlottesville University, Virginia) purified as described (Oleksy et al., 2004 ). Exchange activities were followed by fluorescence resonance energy transfer (FRET) between the GTPase tryptophanes ( ex=292nm) and the methylanthranyloil group of mant-GTP ( em=440nm) as described (Zeeh et al., 2006) . All fluorescence measurements were performed with a CARY Eclipse fluorimeter (Varian). For each k obs determination, RhoA
(1 M) and Tgat (or Trio DH2) were preincubated 3 min at 25°C in 700 L reaction buffer (50 mM Tris pH 7.5, 50 mM NaCl, 2 mM MgCl 2 , 1 mM DTT). The exchange reaction was initiated by 10 M mant-GTP and measured for 10 min until the plateau was reached. Nucleotide exchange inhibition assays -Radioactive [ 3 H]-GDP dissociation assays were performed as described . Briefly, 0.15 M GST-Trio DH2-PH2 was pre- Cell lines, transfection and focus formation assay -NIH3T3 cells were maintained as described previously (Sirvent et al., 2007) .
Transient transfection experiments were performed using the Jet PEI reagent, according to the manufacturer's protocol (QBiogene Inc.). NIH3T3 cell lines stably expressing GFP-Tgat, GFP-Tgat L190E , or GFP-Trio, with or without the GST-TRIP peptides, were generated as follows : the indicated retroviral constructs were transfected into BOSC packaging cells, using the Lipofectamine reagent (Invitrogen Inc.). Forty-eight hours after transfection, viruscontaining supernatants were collected and used to infect NIH3T3 cells. Infected cells were selected with 6 g/mL puromycin and/or 1mg/mL G418 and stable transfectants were pooled after selection. Tgat or TRIP mRNA levels in the different cell lines were monitored by RT-PCR, and protein expression levels by Western blot analysis using a polyclonal anti-GFP antibody (Torrey Pines Laboratories).
Focus formation assays were performed using stable NIH3T3 cell lines as indicated, seeded at 5x10 4 cells in 6-well plates and maintained for 15 to 21 days in 10% FBS. Medium was renewed every two days. After staining with Crystal Violet (1%), plates were photographed and foci were scored using the Metamorph software. All experiments were done in triplicate.
RhoA activation assay in cells -
The level of GTP-bound RhoA was measured by a GST pulldown assay as described . Briefly, cell lysates were incubated with Mice and xenografting -Female Balb/c nu/nu mice were purchased from Charles River
France and used at 6-8 weeks of age. 12 Balb/c nu/nu mice were subcutaneously grafted with 
